Platelet Function and Plasma Fibrinogen and their Relations to Gender, Smoking Habits, Obesity and Beta-Blocker Treatment in Young Survivors of Myocardial Infarction

Ulf Berglund; Lars Wallentin; Henning von Schenck

doi:10.1055/s-0038-1647627

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1988; 60(01): 021-024
DOI: 10.1055/s-0038-1647627

Original Article

Schattauer GmbH Stuttgart

Platelet Function and Plasma Fibrinogen and their Relations to Gender, Smoking Habits, Obesity and Beta-Blocker Treatment in Young Survivors of Myocardial Infarction

Authors

Ulf Berglund

The Department of Internal Medicine, University Hospital, Linköping, Sweden
Lars Wallentin

The Department of Internal Medicine, University Hospital, Linköping, Sweden
Henning von Schenck

^*The Department of Clinical Chemistry, University Hospital, Linköping, Sweden

Abstract

PDF Download

Summary

Seventy-three (58 men and 15 women) survivors of myocardial infarction below 45 years of age and 73 healthy matched controls were investigated regarding in vitro platelet aggregability to ADP and collagen, platelet sensitivity to prostacyclin and plasma levels of beta-thromboglobulin, platelet factor 4 and fibrinogen. The patients, studied 3-6 months after the acute event, had a reduced platelet sensitivity to prostacyclin. They did not differ from the controls regarding the other platelet function tests. Females had higher platelet reactivity than men. Smoking, obesity or beta- blocker treatment did not influence platelet function. The patients had higher fibrinogen levels than the controls. Gender did not influence, while smoking and obesity increased plasma fibrinogen. Patients on beta-blockade had lower fibrinogen levels than patients without this therapy. The high fibrinogen level and the low platelet sensitivity to prostacyclin might indicate an increased thrombotic liability in young myocardial infarction patients.

Key words

Platelet function - Platelet sensitivity to prostacyclin - Fibrinogen - Myocardial infarction - Beta-blocker treatment

PDF (954 kb)

References

References
1 Wood MA De, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902
2 Davies MJ, Thomas AC. Plaque fissuring – the cause of acute myocardial infarction, sudden ischaemic death and crescendo angina. Br Heart J 1985; 53: 363-373
3 Maseri A, Chierchia S, Davies G. Pathophysiology of coronary occlusion in acute infarction. Circulation 1986; 73: 233-239
4 Roskamm H, Gohlke H, Sturzenhofecker P, Droste C, Thomas H, Samek L, Schnellbacher K, Betz P. Der Herzinfarkt im jugendlichen Alter (unter 40 Jahren): Koronarmorphologie, Langzeitprognose der Erkrankung und Progression der Koronargefäßsklerose. Z Kardiol 1983; 72: 1-11
5 Hoit BD, Gilpin EA, Henning H, Maisei AA, Dittrich H, Carlisle J, Ross Jr J. Myocardial infarction in young patients: an analysis by age subsets. Circulation 1986; 74: 712-721
6 Wei JY, Bulkley BH. Myocardial infarction before age 36 years in women: Predominance of apparent nonatherosclerotic events. Am Heart J 1982; 104: 561-566
7 Hamsten A, Blombäck M, Wiman B, Svensson J, Szamosi A, De Faire U, Mettinger L. Haemostatic function in myocardial infarction. Br Heart J 1986; 55: 58-66
8 Hamsten A, Svensson J, Walldius G, Szamosi A, De Faire U. Shortened megakaryocyte-platelet regeneration time in young survivors of myocardial infarction. Am Heart J 1985; 110: 1154-1160
9 Fuster V, Chesebro JH, Frye RL, Elveback LR. Platelet survival and the development of coronary artery disease in the young adult: effects of cigarette smoking, strong family history and medical therapy. Circulation 1981; 63: 546-551
10 Vilen L, Johansson S, Kutti J, Cronberg S, Vedin A, Wilhelmsson C. ADP-induced platelet aggregation in young female survivors of acute myocardial infarctioin and their female controls. Acta Med Scand 1985; 217: 9-13
11 Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979; 59: 607-609
12 Berglund U, Von Schenck H, Wallentin L. Effects of Ticlopidine on platelet function in men with stable angina pectoris. Thromb Haemostas 1985; 54: 808-812
13 Sinzinger H, Schernthaner G, Kaliman J. Sensitivity of platelets to prostaglandins in coronary heart disease and angina pectoris. Prosta-glandins 1981; 22: 773-781
14 Ludlam CA, Cash JD. Studies on the liberation of beta-thromboglobulin from human platelets in vitro. Br J Haematol 1976; 33: 239-247
15 Desvignes P, Bonnet P. Direct determination of plasma fibrinogen levels by heat precipitation. A comparison of the technique thrombin clottable fibrinogen with spectophotometry and radial immunodiffusion Clin Chim Acta 1981; 110: 9-17
16 Swahn E, Wallentin L. Platelet reactivity in unstable coronary artery disease. Thromb Haemostas 1987; 57: 302-305
17 Mueller HS, Rao PS, Greenberg MA, Buttrick PM, Sussman II, Levite HA, Grose RM, Perez-Davila V, Strain JE, Spaet TH. Systemic and transcardiac platelet activity in acute myocardial infarction in man: resistance to prostacyclin. Circulation 1985; 72: 1336-1345
18 Sorkin RP, Tokarsky JM, Huber-Smith MJ, Steiger JF, McCann DS. In vivo platelet aggregation and plasma catecholamines in acute myocardial infarction. Am Heart J 1982; 104: 1255-1261
19 Buttrick PM, Forscher CA, Sussman II, Mueller HS. Subaggregatory doses of catecholamines prevent prostacyclin-induced inhibition of platelet aggregation. Am Heart J 1985; 109: 1258-1264
20 Neri Serneri GG, Modesti PA, Fortini A, Abbate R, Lombardi A, Gensini GF. Reduction in prostacyclin platelet receptors in spontaneous angina. Lancet 1984; 2: 838-841
21 Nadler JL, Velasco JS, Horton R. Cigarette smoking inhibits prostacyclin formation. Lancet 1983; 1: 1248-1250
22 Sinzinger H, Kefalides A. Passive smoking severely decreases platelet sensitivity to antiaggregatory prostacyclin. Lancet 1982; 2: 392-393
23 Levine PH. An acute effect of cigarette smoking on platelet function. Circulation 1973; 48: 619-623
24 Szczeklik A, Gryglewski RJ, Musial J, Grodzinska L, Serwonska M, Marcinkiewicz E. Thromboxane generation and platelet aggregation in survivals of myocardial infarction. Thromb Haemostas 1978; 40: 66-74
25 Hughes A, Daunt S, Vass G, Wickes J. In vivo platelet activation following myocardial infarction and acute coronary ischemia. Thromb Haemostas 1982; 48: 133-135
26 Pengo V, Boschello M, Prandoni P, Schiavon R, Bellotto F, Schivazappa L, Dalla Volta S. Enhanced “in vitro” release of platelet alfa-granules after acute myocardial infarction (AMI). Thromb Haemostas 1985; 54: 544-546
27 Jaffe AS, Lee RG, Perez JE, Geltman EM, Wilner GB, Sobel BE. Lack of elevation of platelet factor IV in plasma from patients with myocardial infarction. J Am Coll Cardiol 1984; 4: 653-659
28 Meade TW, Vickers MV, Thompson SG, Sterling Y, Haines AP, Miller GJ. Epidemiological characteristics of platelet aggregability. Br Med J 1985; 290: 428-432
29 Greer IA, Walker JJ, McLaren M, Calder AA, Forbes CD. A comparative study of the effects of adrenoceptor antagonists on platelet aggregation and thromboxane generation. Thromb Haemostas 1985; 54: 480-484
30 Callahan KS, Johnson AR, Campbell WB. Enhancement of the antiaggregatory activity of prostacyclin by propranolol in human platelets. Circulation 1985; 71: 1237-1246
31 Dale J, Landmark KH, Myhre E. The effects of nifedipine, a calciumantagonist, on platelet function. Am Heart J 1983; 105: 103-105
32 Ring ME, Corrigan Jr JJ, Fenster PE. Effects of oral diltiazem on platelet function: alone and in combination with “low dose” aspirin. Thromb Res 1986; 44: 391-400
33 Born GV R, Hardesty RM. Platelets. In: 2. ed Biggs R. (ed) Human Blood Coagulation, Haemostasis and Thrombosis. Blackwell; Oxford: 1976: 180
34 Meade TW, Chakrabarti R, Haines AP, North WRS, Sterling Y, Thompson SG. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 1050-1054
35 Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
36 O’Connor NT J, Cederholm-Williams S, Copper S, Cotter L. Hypercoagulability and coronary artery disease. Br Heart J 1984; 52: 614-616
37 Meade TW, Chakrabarti R, Haiones AP, North WR S, Sterling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J 1979; 1: 153-156
38 Baker IA, Eastham R, Elwood PC, Etherington M, O’Brien JR, Sweetnam PM. Hemostatic factors associated with ischemic heart disease in men aged 45—64 years. The Speedwell study. Br Heart J 1982; 47: 490-494
39 Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707-1714
40 Olsson G, Rehnqvist N, Sjögren A, Erhardt L, Lundman T. Longterm treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol 1985; 5: 1428-1437
41 Mehrotra TN, Mitai HS, Singh VS, Kumar A, Sinha AK, Raka MS. Platelet adhesiveness, plasma fibrinogen and fibrinolytic activity in angina pectoris before and after propranolol treatment. J Assoc Physicians India 1983; 31: 641-643
42 Caimi G, Catania A, Frazzetta F, Copobianco D, Sarno A. The behaviour of the haemorheological determinants and their trends during beta-blocker treatment. Jpn Heart J 1983; 24: 723-729